New Cannabinoid May Have Potential to Enhance Breast Cancer Treatment
This cannabinoid has shownpotential for breast cancer treatments
A groundbreaking study from the Technion – Israel Institute of Technology has unveiled an exciting new compound from the cannabis plant, known as cannabinoid 373.15b. This innovative cannabinoid has shown promising potential in improving breast cancer treatments by making cancer cells more responsive to standard hormonal therapies.
What is Cannabinoid 373.15b?
Cannabinoid 373.15b is a unique phytocannabinoid derived from a specific cannabis extract called CANN14. What sets it apart is its distinctive chemical structure, which includes an acetate group on its aromatic ring. Unlike typical cannabinoids that interact with the body's endocannabinoid system, 373.15b targets estrogen receptors directly.
How Does Cannabinoid 373.15b Work?
Cannabinoid 373.15b operates differently than traditional cannabinoids. Instead of unlocking the body’s endocannabinoid receptors (CB1 and CB2) like most compounds, it directly influences estrogen receptors. This is crucial for treating ER-positive breast tumors, which depend on estrogen for growth. By reducing the activity of the estrogen receptor alpha (ERα), cannabinoid 373.15b effectively slows down the cancer cells' growth.
What is the Synergy with Tamoxifen?
One of the most exciting findings from the study is the strong interaction between cannabinoid 373.15b and Tamoxifen, a common Selective Estrogen Receptor Modulator (SERM) used in breast cancer treatment. In preclinical tests on mice, combining cannabinoid 373.15b with Tamoxifen significantly reduced tumor volume and weight compared to using either treatment alone.
What Does This Mean for Breast Cancer Patients?
The promising synergy between cannabinoid 373.15b and Tamoxifen opens new avenues for breast cancer treatment. This combination therapy may allow for a lower dosage of Tamoxifen, which could lessen its side effects and improve the overall quality of life for patients.
What is the Importance of Cannabis Research?
The discovery of cannabinoid 373.15b underscores the remarkable chemical diversity of the cannabis plant. It highlights the potential for new pharmacological tools that could significantly benefit cancer treatment strategies.
Should Patients Consider Cannabinoid 373.15b?
While cannabinoid 373.15b shows great promise, it is important to remember that cannabis and its derivatives should not replace traditional cancer treatments. Always consult with an oncologist or medical professional before making any changes to your treatment plan.
By understanding the potential of cannabinoids like 373.15b, we can explore innovative approaches to enhancing breast cancer care and improving patient outcomes.
More From Soft Secrets
Meta-analysis examines thousands of cannabis cancer studies
L
Liz Filmer
